¼¼°èÀÇ ¼ÒÈ­°ü ½ÅÀ强 ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå
Gastroretentive Drug Delivery Systems
»óǰÄÚµå : 1774872
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¼ÒÈ­°ü ½ÅÀ强 ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2030³â±îÁö 199¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 151¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼ÒÈ­°ü ½ÅÀ强 ¾à¹°Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 199¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÎÀ¯½Ä ¾à¹°Àü´Þ ½Ã½ºÅÛÀº CAGR 3.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 67¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. È®ÀåÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 6.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 41¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼ÒÈ­°ü ½ÅÀ强 ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2024³â¿¡ 41¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 38¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 7.1%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.3%¿Í 4.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.9%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¼ÒÈ­°ü ½ÅÀ强 ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼ÒÈ­°ü È®ÀåÇü ¾à¹° Àü´Þ ½Ã½ºÅÛÀÌ °æ±¸ ¾à¹° Ä¡·á¿¡ º¯È­¸¦ °¡Á®¿Ã ¼ö ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¼ÒÈ­°ü È®ÀåÇü ¾à¹° Àü´Þ ½Ã½ºÅÛ(GRDDS)Àº ¾à¹°ÀÌ À§Àå¿¡ ¿À·¡ ¸Ó¹«¸¦ ¼ö ÀÖµµ·Ï ÇÏ¿© Èí¼ö¿Í »ýü ÀÌ¿ë·üÀ» Çâ»ó½ÃÅ´À¸·Î½á °æ±¸ ¾à¹° Åõ¿©¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº »óºÎ ¼ÒÈ­°ü¿¡¼­ Èí¼ö âÀÌ Á¼Àº ¾à¹°À̳ª ¾ËÄ®¸®¼º Á¶°Ç¿¡¼­ ºÐÇØµÇ´Â ¾à¹°¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. GRDDS´Â ¾à¹°ÀÇ À§ ³» ü·ù ½Ã°£À» ¿¬ÀåÇÔÀ¸·Î½á ¾à¹°ÀÇ Ä¡·á È¿°ú¸¦ ³ôÀÌ´Â µ¿½Ã¿¡ Åõ¿© Ƚ¼ö¸¦ ÁÙ¿© ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

ºÎÀ¯¼º, »ýüÁ¢Âø¼º, ÆØÃ¢¼º, ÆØÃ¢¼º ¾à¹°Àü´Þ½Ã½ºÅÛ°ú °°Àº À§³» ü·ù¼º ±â¼úÀÇ °³¹ßÀº Á¦¾àȸ»ç¿¡ ¾à¹°ÀÇ ¼º´ÉÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ´Â Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇØ ¿Ô½À´Ï´Ù. ºÎÀ¯Çü ¾à¹° Àü´Þ ½Ã½ºÅÛ(FDDS)Àº °¡Àå ³Î¸® »ç¿ëµÇ´Â ½Ã½ºÅÛ Áß Çϳª·Î, À§¾×¿¡¼­ ºÎÀ¯¼ºÀ» À¯ÁöÇÏ´Â Àú¹Ðµµ Á¦Á¦¸¦ ÀÌ¿ëÇÏ¿© Áö¼ÓÀûÀÎ ¾à¹° ¹æÃâÀ» º¸ÀåÇÕ´Ï´Ù. ¸¶Âù°¡Áö·Î, »ýü Á¢Âø ½Ã½ºÅÛÀº À§ Á¡¸·¿¡ ºÎÂøµÇ¾î ¾à¹°ÀÇ Èí¼ö ºÎÀ§¿ÍÀÇ Á¢ÃË ½Ã°£À» ¿¬ÀåÇÕ´Ï´Ù. Á¦¾àȸ»çµéÀÌ ¾à¹° ¿ëÇØµµ¿Í ¹æÃâ Á¦¾î ¸ÞÄ¿´ÏÁòÀ» °³¼±ÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ´Â °¡¿îµ¥ GRDDS´Â ÃֽŠ°æ±¸¿ë ¾à¹° Á¦Á¦ÀÇ ÇʼöÀûÀÎ ºÎºÐÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼ÒÈ­°ü È®ÀåÇü ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇÏ´Â Ä¡·á ºÐ¾ß´Â ¹«¾ùÀΰ¡?

¼ÒÈ­°ü È®ÀåÇü ¾à¹°Àü´Þ½Ã½ºÅÛÀº À§ÀåÀå¾Ö, ´ç´¢º´, ½ÉÇ÷°üÁúȯ, °¨¿° µî ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, GERD ¹× ¼ÒÈ­¼º ±Ë¾ç Ä¡·á¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦(PPI) ¹× H2 ¼ö¿ëü ±æÇ×Á¦´Â ÃÖÀûÀÇ È¿°ú¸¦ ¾ò±â À§ÇØ Àå½Ã°£ À§ ³» ü·ù°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ GRDDSÀÇ ÇýÅÃÀ» Å©°Ô ´©¸± ¼ö ÀÖ½À´Ï´Ù. ÃÖÀûÀÇ È¿°ú¸¦ ¾ò±â À§ÇØ Àå±â°£ À§ ³» ü·ù°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ GRDDS·ÎºÎÅÍ Å« ÇýÅÃÀ» ¹Þ½À´Ï´Ù. ¸¶Âù°¡Áö·Î Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® Á¦±Õ ¿ä¹ý¿¡ »ç¿ëµÇ´Â ¾Æ¸ñ½Ã½Ç¸°, ¸ÞÆ®·Î´Ï´ÙÁ¹°ú °°Àº Ç×»ýÁ¦ ¿ª½Ã Á¦±ÕÀ²À» ³ôÀ̱â À§ÇØ À§³» ü·ù¼º Á¦Á¦¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

´ç´¢º´ °ü¸® ºÐ¾ß¿¡¼­ GRDDS´Â »óºÎ ¼ÒÈ­°ü¿¡¼­ Èí¼öµÇ´Â ½Ã°£ÀÌ Á¦ÇÑÀûÀÎ ¸ÞÆ®Æ÷¸£¹Î°ú °°Àº ¾à¹°ÀÇ »ýü ÀÌ¿ë·üÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ½ºÅ¸Æ¾, º£Å¸Â÷´ÜÁ¦ µî ½ÉÇ÷°ü°è ¾à¹°µµ ¾à¹° ¹æÃâÀ» Á¶ÀýÇϰí ȯÀÚÀÇ º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½Ã۱â À§ÇØ À§³» ü·ù¼º ±â¼úÀ» ÀÌ¿ëÇÑ Á¦ÇüÀÌ °³¹ßµÇ°í ÀÖÀ¸¸ç, GRDDS¿¡ ´ëÇÑ ¼ö¿ä´Â ÅëÁõ °ü¸® ¹× ÁßÃ߽Űæ°è(CNS) ÀǾàǰ ºÐ¾ß¿¡¼­ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°ÀÇ ¼­¹æÈ­¸¦ ÅëÇØ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí Ä¡·á ¼ºÀûÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

À§³» ü·ù¼º ¾à¹° Àü´ÞÀ» °­È­ÇÏ´Â ±â¼ú Çõ½Å¿¡´Â ¾î¶² °ÍµéÀÌ ÀÖÀ»±î¿ä?

°íºÐÀÚ °úÇаú ³ª³ë±â¼úÀÇ ¹ßÀüÀ¸·Î ¼ÒÈ­°ü È®À强 ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ È¿´ÉÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ½º¸¶Æ® Æú¸®¸Ó¸¦ ±â¹ÝÀ¸·Î ÇÑ Á¦Á¦°¡ °³¹ßµÇ¾î À§ ³» ÆØÃ¢, ÆØÃ¢ ¹× °íÂøÀ» Á¦¾îÇÏ°í ¾à¹° ¹æÃâ ¼Óµµ¸¦ ÃÖÀûÈ­Çß½À´Ï´Ù. ¶ÇÇÑ, ³ª³ë Á¦Á¦´Â ³­¼ö¿ë¼º ¾à¹°ÀÇ ¿ëÇØ¼º°ú Èí¼ö¼ºÀ» Çâ»ó½ÃÄÑ º¸´Ù È¿À²ÀûÀÎ ¾à¹° Àü´ÞÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ Å« Çõ½ÅÀº GRDDS¿¡ ¸¶ÀÌÅ©·Î ÀÏ·ºÆ®·Î´Ð½º ¸ð´ÏÅ͸µÀ» ÅëÇÕÇÏ¿© ¾à¹° ¹æÃâ°ú À§³» ü·ù·®À» ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖµµ·Ï ÇÑ °ÍÀÔ´Ï´Ù. ¼¾¼­°¡ ³»ÀåµÈ ½º¸¶Æ® Á¤Á¦´Â ¾à¹° Èí¼ö ÆÐÅÏ¿¡ ´ëÇÑ µ¥ÀÌÅ͸¦ Àǻ翡°Ô Á¦°øÇÏ¿© °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» °³¼±ÇÒ ¼ö ÀÖÀ¸¸ç, 3D ÇÁ¸°ÆÃ ±â¼ú ¶ÇÇÑ ¸ÂÃãÇü À§³» ü·ù¼º ¾à¹° Á¦Á¦¸¦ °³¹ßÇϱâ À§ÇØ ¿¬±¸µÇ°í ÀÖ¾î ¾à¹° ¹æÃâ ÇÁ·ÎÆÄÀÏÀ» Á¤¹ÐÇÏ°Ô Á¦¾îÇÒ ¼ö ÀÖ½À´Ï´Ù. °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀ¸·Î GRDDS´Â ´õ¿í È¿°úÀûÀ̰í ÀûÀÀ¼ºÀÌ ³ôÀ¸¸ç ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á¹ýÀ¸·Î °Åµì³ª°í ÀÖ½À´Ï´Ù.

¼ÒÈ­°ü È®ÀåÇü ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼ÒÈ­°ü È®ÀåÇü ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº À§À庴 À¯º´·ü Áõ°¡, ¹æÃâ Á¦¾îÇü Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °íºÐÀÚ ±â¹Ý Àü´Þ ±â¼úÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. »ýü ÀÌ¿ë·üÀ» ³ôÀÎ Àå±â Åõ¾àÀÌ ÇÊ¿äÇÑ ³ëÀÎ Àα¸ Áõ°¡µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¦¾à¾÷°è°¡ ȯÀÚ Áß½ÉÀÇ Á¦Çü¿¡ ÁßÁ¡À» µÎ¸é¼­ GRDDS ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÈ÷ ´ç´¢º´ ¹× ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ Ä¡·á¿¡¼­ À§³» ü·ù¼º Á¦Á¦ÀÇ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº »ó¿ëÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À ÀǾàǰ ¿¬±¸ÀÇ È®´ë¿Í Çõ½ÅÀûÀÎ ¾à¹° Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ Ã¤ÅÃÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀÌ »õ·Î¿î ¾à¹° Á¦Á¦¸¦ Áö¼ÓÀûÀ¸·Î Ž»öÇÔ¿¡ µû¶ó ¼ÒÈ­°ü È®ÀåÇü ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© °æ±¸¿ë ¾à¹° Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯Çü(ºÎÀ¯Çü ¾à¹°Àü´Þ ½Ã½ºÅÛ, È®ÀåÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ, »ýü Á¢ÂøÇü ¾à¹°Àü´Þ ½Ã½ºÅÛ, °í¹Ðµµ ½Ã½ºÅÛ, ±âŸ ¼ÒÈ­°ü ½ÅÀ强 ¾à¹°Àü´Þ ½Ã½ºÅÛ), Åõ¿©·®(Á¤Á¦ Åõ¿©·®, ĸ½¶ Åõ¿©·®, °Ö Åõ¿©·®, ¾×ü Åõ¿©·®, ±âŸ Åõ¿©·®), À¯Åë ä³Î(º´¿ø ¾à±¹ À¯Åë ä³Î, ¼Ò¸Å ¾à±¹ À¯Åë ä³Î, ¿Â¶óÀÎ ¾à±¹ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõ µÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gastroretentive Drug Delivery Systems Market to Reach US$19.9 Billion by 2030

The global market for Gastroretentive Drug Delivery Systems estimated at US$15.1 Billion in the year 2024, is expected to reach US$19.9 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Floating Drug Delivery System, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Expandable Drug Delivery System segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 7.1% CAGR

The Gastroretentive Drug Delivery Systems market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Gastroretentive Drug Delivery Systems Market - Key Trends & Drivers Summarized

Why Are Gastroretentive Drug Delivery Systems Transforming Oral Drug Therapies?

Gastroretentive drug delivery systems (GRDDS) have revolutionized oral drug administration by enabling prolonged retention of drugs in the stomach, improving absorption and bioavailability. These systems are particularly beneficial for drugs with a narrow absorption window in the upper gastrointestinal tract or those that degrade in alkaline conditions. By ensuring extended gastric residence time, GRDDS enhance the therapeutic efficacy of drugs while reducing dosing frequency, leading to improved patient compliance.

The development of gastroretentive technologies, such as floating, bioadhesive, swelling, and expandable drug delivery systems, has provided pharmaceutical companies with innovative solutions to optimize drug performance. Floating drug delivery systems (FDDS) are among the most widely used, utilizing low-density formulations that remain buoyant in gastric fluids, ensuring sustained drug release. Similarly, bioadhesive systems adhere to the gastric mucosa, prolonging drug contact time with absorption sites. As pharmaceutical companies focus on improving drug solubility and controlled release mechanisms, GRDDS are becoming an integral part of modern oral drug formulations.

Which Therapeutic Areas Are Driving Demand for Gastroretentive Drug Delivery Systems?

Gastroretentive drug delivery systems are widely used across multiple therapeutic areas, including gastrointestinal disorders, diabetes, cardiovascular diseases, and infectious diseases. Proton pump inhibitors (PPIs) and H2-receptor antagonists, commonly used for GERD and peptic ulcer treatment, benefit significantly from GRDDS, as they require prolonged gastric retention for optimal effectiveness. Similarly, antibiotics such as amoxicillin and metronidazole used in Helicobacter pylori eradication therapy leverage gastroretentive formulations to enhance bacterial eradication rates.

In the diabetes management sector, GRDDS are improving the bioavailability of drugs such as metformin, which has a limited absorption window in the upper GI tract. Cardiovascular drugs, including statins and beta-blockers, are also being formulated with gastroretentive technologies to improve controlled drug release and patient adherence. The demand for GRDDS is further expanding in the pain management and central nervous system (CNS) drug sectors, where sustained drug release can minimize side effects and improve therapeutic outcomes.

What Technological Innovations Are Enhancing Gastroretentive Drug Delivery?

Advancements in polymer science and nanotechnology have significantly improved the effectiveness of gastroretentive drug delivery systems. Smart polymer-based formulations are being developed to achieve controlled swelling, expansion, and adherence within the stomach, optimizing drug release kinetics. Additionally, nano-formulations are enhancing the solubility and absorption of poorly water-soluble drugs, ensuring more efficient drug delivery.

Another major innovation is the incorporation of microelectronic monitoring in GRDDS, allowing real-time tracking of drug release and gastric retention. Smart pills with embedded sensors can provide physicians with data on drug absorption patterns, improving personalized treatment approaches. 3D printing technology is also being explored to develop customized gastroretentive drug formulations, enabling precise control over drug release profiles. These technological advancements are making GRDDS more effective, adaptable, and patient-friendly.

What Factors Are Fueling the Growth of the Gastroretentive Drug Delivery Systems Market?

The growth in the gastroretentive drug delivery systems market is driven by several factors, including the increasing prevalence of gastrointestinal diseases, rising demand for controlled-release drug formulations, and advancements in polymer-based delivery technologies. The growing geriatric population, which requires long-term medication with improved bioavailability, has also contributed to market expansion.

The pharmaceutical industry’s focus on patient-centric drug formulations has led to increased investment in GRDDS research and development. Additionally, regulatory approvals for gastroretentive formulations are driving their commercialization, particularly in the treatment of chronic diseases such as diabetes and cardiovascular disorders. The expansion of biopharmaceutical research and the adoption of innovative drug delivery mechanisms are further propelling market growth. As pharmaceutical companies continue to explore novel drug formulations, the demand for gastroretentive drug delivery systems is expected to grow, shaping the future of oral drug therapies.

SCOPE OF STUDY:

The report analyzes the Gastroretentive Drug Delivery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Floating Drug Delivery System, Expandable Drug Delivery System, Bioadhesive Drug Delivery System, High Density Systems, Other Gastroretentive Drug Delivery Systems); Dosage (Tablets Dosage, Capsule Dosage, Gel Dosage, Liquid Dosage, Other Dosages); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â